PATENT CLAIM ANALYSIS

Application Number: 15892229
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["548", "253000"]

Abstract:
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

Claim (Index 83):
A method of treating an autoimmune disorder comprising the step of administering to a subject in need thereof an effective amount of a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof, wherein the autoimmune disorder is chronic obstructive pulmonary disease, inflammatory bowel disease, allergic rhinitis, asthma, multiple sclerosis, psoriasis, Crohn's disease, colitis, ulcerative colitis, arthritis, bone diseases associated with increased bone resorption, or chronic obstructive airway disease.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 88.0
- Lexical Diversity: 1.58974
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14539470', '12899416', '15635268', '12899410', '14626522']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8173422229788007
- 35 USC 102 Novelty (BERT): 0.6160006852058285
- Combined Prediction Score: 0.7972080692015034
- Mean Citation Score: 511.481862
- Max Citation Score: 550.60614
- Similarity Product: 539.4993786190938

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test